Abstract
We tested the hypothesis that GnRH agonist treatment of CPP is associated with loss of bone mineral density (BMD) and content (BMC) after young women treated with GnRH agonists were reported to lose up to 6% BMD in the first treatment year similar to that seen during menopause. We determined lumbar spine (L1-L4) BMD (g/cm2) and BMC (g) by dual photon absorptiometry and measured growth parameters and blood Ca (mg/dl), alk. phos. (AP, mU/ml) and integrated growth hormone (GH, ng/ml) on CPP patients before and after (3 of our 6 patients to date) six months treatment with the GnRH agonist LUPRON (TAP Pharm., 4-8 ug/kg SC qD). Our patients (3 girls 5-8 yr, 9-10 yr bone age [BA]; 3 boys 3-8 yr, 7-10 yr BA) were Stage 3-4 upon entering the study with informed consent.
All 6 had similar basal BMD (.724±.05, SEM). Despite reduction of V or T toward prepubertal levels, growth rates and BMC did not decline and GH and BMD increased while Ca and AP decreased.
We conclude that early, partial suppression of CPP with LUPRON is not associated with loss of BMD or BMC. Followup with further suppression of CPP should help to distinguish between variable time courses of end organ responses or therapeutic selectivity.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moll, G., Collins, D., Depuey, G. et al. LUPRON TREATMENT OF PRECOCIOUS PUBERTY (CPP) HAS NOT PRODUCED LOSS OF BONE MINERAL. Pediatr Res 21 (Suppl 4), 251 (1987). https://doi.org/10.1203/00006450-198704010-00504
Issue Date:
DOI: https://doi.org/10.1203/00006450-198704010-00504